The viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from an estimated USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by effectiveness of viral vectors in gene therapy delivery. Viral vectors have been proven to be effective tools for delivering therapeutic genes to target cells in gene therapy. The effectiveness of viral vectors can depend on several factors, including the type of virus used, the target cell type, the dosage and mode of delivery, and the immune response of the patient. Viral vectors can be modified according to the required application and thus prove advantageous for targeting and entering cells.
The global market is a consolidated market, with Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US) and FUJIFILM Corporation (Japan) together accounting for ~65–75% of the global market.
To know about the assumptions considered for the study download the pdf brochure
Lonza Group(Switzerland) is a global life sciences company that provides integrated solutions and products to various markets, including pharmaceuticals, biotech, nutrition, and personal care. Lonza's core capabilities lie in the areas of research, development, manufacturing, and commercialization. It offers a wide range of services and products, including active pharmaceutical ingredients (APIs), drug delivery technologies, cell and gene therapies, microbial control solutions, and specialty chemicals. The company operates through four key business segments namely, Biologics, Small Molecules, Cell & Gene and Capsule & Health Ingredients. The company offers viral vector and plasmid DNA manufacturing products and services through its biologics and cell & gene therapy segment.
The company focuses on organic and inorganic growth strategies such as product launch, collaborations, and partnerships to strengthen its presence in the viral vector and plasmid DNA manufacturing market. The company has launched in recent years, such as TheraPEAK SfAAV Medium, an a first chemically defined, non-animal origin medium designed specifically to produce Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications. The company focuses on improving its R&D capabilities to unlock additional synergies and growth opportunities.
Merck KGaA(Germany) is a healthcare and life science company that develops, manufactures, and markets pharmaceutical and biopharmaceutical products, specialty chemicals, high-tech materials, and life science research and diagnostic tools. The company operates through three business segments- Healthcare, Life Science, and Electronics. The Life Science segment is further segmented into Process Solutions, Science & Lab Solutions, and Life Science Services. The company operates in the viral vector and plasmid DNA manufacturing market through the Process Solutions division of life science segment.
The company provides process development and optimization services to help biopharmaceutical companies in their viral vector and plasmid DNA manufacturing endeavors. These services include process scale-up, optimization, and characterization, with the aim of improving efficiency, yield, and quality. By leveraging its expertise and offerings in cell culture, molecular biology, and process development, Merck KGaA can support biopharmaceutical companies throughout various stages of viral vector and plasmid DNA manufacturing processes.
Thermo Fisher Scientific Inc. (US) is one of the leading players in the life science industry, with a strong market presence in more than 80 countries. The company is involved in the development, manufacturing, sales, and distribution of analytical instruments, equipment, reagents and consumables, software, and services. The company operates its business through four key segments—Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company offers viral vector and plasmid DNA manufacturing products and services through the Life Sciences Solutions business.
The company has the infrastructure and expertise to support clients in various stages of viral vector development. By partnering with Thermo Fisher Scientific Inc., for viral vector manufacturing, biopharmaceutical companies can leverage their experience and resources to accelerate the development and production of gene therapies and vaccines. This allows clients to focus on the core aspects of their research and development while relying on Thermo Fisher Scientific Inc., expertise in manufacturing and regulatory compliance.
Viral Vector Manufacturing Market by Type (Viral Vector [Retroviruses, Adenoviruses, AAV, Lentiviruses], Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User & Region - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE